Compare Incyte Corporation (INCY) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.6 (market cap $311.72M). The key difference: Incyte Corporation is far larger — about 73.3× Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037's market cap, and Incyte Corporation is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 for 48 Days on average.
| INCY | USOI | |
|---|---|---|
Market Cap | $22.85B | $311.72M |
Volume | 1,927,029 | 75,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $129.93 | $61.17 |
52-Week Low | $83.80 | $42.27 |
Typical Hold Time | 33 Days | 48 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
USOI trades at $45.60, up 2.22% today, but technical indicators signal bearish momentum with moving averages showing 9 sell signals versus 4 buys. The stock faces resistance at $46 with support at $44. Financial ratios remain unavailable in current data, limiting fundamental assessment.
The bearish technical outlook suggests near-term pressure, though neutral oscillators indicate potential consolidation. Investment appeal is constrained by incomplete fundamental data. Key risks include market volatility and lack of visibility into financial performance metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
